✦ LIBER ✦

Predictors of response to the 13.3 and 9.5mg/24h rivastigmine patch: The optimizing /INS;transdermal exelon in mild-to-moderate Alzheimer's disease (optima) study

✍ Scribed by Molinuevo, J.L.; Grossberg, G.; Frölich, L.; Galvin, J.; Krahnke, T.; Strohmaier, C.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence and predictors of response to

✍ Molinuevo, Jose Luis; Grossberg, George; Frölich, Lutz; Galvin, James; Krahnke, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 150 KB

The rivastigmine high-dose, 13 mg/24h (1

✍ Cummings, Jeffrey; Bellelli, Giuseppe; Black, Sandra; Bakchine, Serge; Krahnke, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Efficacy of the 13.3 mg/24 h rivastigmin

✍ Black, Sandra; Bakchine, Serge; Bellelli, Giuseppe; Molinuevo, Jose Luis; Downs, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Comparisons of patient characteristics i

✍ Frolich, Lutz; Monsch, Andreas; Kressig, Reto; Downs, Pamela; Caputo, Angelika; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

High-dose 13.3mg/24h rivastigmine patch

✍ Molinuevo, J.L.; Cummings, J.; Frölich, L.; Galvin, J.; Krahnke, T.; Strohmaier, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Efficacy, safety and tolerability of riv

✍ Farlow, Martin; Meng, Xiangyi; Rensch, Scott; Somogyi, Monique 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 49 KB